REFERENCES
- de la Rosette JJMCH, d'Ancona FCH, Debruyne FMJ. Current status of thermotherapy of the prostate. J Urol 1997; 157: 430–8.
- Devonec M, Ogden C, Perrin P, Carter S. Clinical response to transurethral microwave thermotherapy is thermal dose dependent. Eur Urol 1996; 23: 267–74.
- de Wildt MJAM, d'Ancona FCH, Hubregtse M, Carter SStC, Debruyne FMJ, de la Rosette JJMCH. Three-year follow-up of patients treated with lower energy micro-wave thermotherapy. J Urol 1996; 156: 1959–63.
- Homma Y, Aso Y. Transurethral microwave thermo-therapy for benign prostatic hyperplasia. J Endourol 1993; 3: 261–5.
- Blute M, Hanson K, Lynch J, Tomera K, Cope P, Sankey N, et al. United States Prostatron TUMT Study-4 year follow-up and quality of life. J Urol 1996; 155\(Part 2): 403A.
- Dwhlin L, Frugird J, Farstad M. Serum concentrations of prostate-specific antigen after diagnostic procedures and transurethral microwave thermotherapy of benign prostatic hyperplasia. Scand J Clin Lab Invest 1996; 56: 269–73.
- Dwhlin L, Frugard J. Transurethral microwave thermo-therapy for management of benign prostatic hyperplasia: one-year results with the PRIMUS U R device. Scand J Urol Nephrol 1997; 31: 57–61.
- Cockett ATK, Aso Y, Denis L, Murphy G, Khoury S, et al. Recommendations of the International Consensus Committee concerning: 1. Prostate Symptom Score (I-PSS) and Quality of Life Assessment. 2. Diagnostic work-up of patients presenting with symptoms sugges-tive of pro statism. 3. Standardization of the evaluation of treatment modalities. 4. BPH treatment recommenda-tions. In: Cockett AT, Khoury S, Aso Y, Chatelain C, Denis L, Griffiths K, et al, editors. The 2nd International Consultation on Benign Prostatic Hyperplasia (BPH). Jersey: Scientific Communication International 1993: 553–64.
- Carter HB, Pearson JD, Metter J, Brant LJ, Chan DW, Andres R, et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 1992; 267: 2215–20.
- Siegel S Nonparametric statistics for the behavioral sciences. Tokyo, McGraw-Hill Kohakusha, 1956.
- NoruSis MJ SPSS(13 for WindowsT . Base system user's guide, release 6.1. Chicago: SPSS Inc., 1994.
- Dahlstrand C, Walden M, Geirsson G, Petterson S. Transurethral microwave thermotherapy versus transur-ethral resection for symptomatic benign prostatic obstruction: a prospective randomized study with a 2-year follow-up. Br J Urol 1995; 76: 614–8.
- Hallin A, Berlin T. Transurethral microwave thermo-therapy for benign prostatic hyperplasia: clinical out-come after 4 years. J Urol 1998; 159: 459–64.
- Brehmer M, Kinn AC. Transurethral microwave ther-motherapy for benign prostatic hyperplasia. Subjective response and urodynamic changes. Scand J Urol Nephrol 1996; 30: 307–11.
- de la Rosette JJMCH, Tubaro A, Trucchi A, Carter S, Hofner K. Changes in pressure-flow parameters in patients treated with transurethral microwave thermo-therapy. J Urol 1995; 154: 1382–5.
- Perachino M, Bozzo W, Puppo P. Vitali A, Ardoino S, Ferro MA. Does transurethral thermotherapy induce a long-term alpha blockade? Eur Urol 1993; 23: 299–301.
- Ogden CW, Reddy P, Johnson H, Ramsay JWA, Carter S. Sham versus transurethral microwave thermotherapy in patients with symptoms of benign bladder outflow obstruction. Lancet 1993; 341: 14–7.
- de la Rosette JJMCH, Wildt de MJAM, Alivizatos G, Froeling FMJA, Debruyne FMJ. Transurethral micro-wave thermotherapy (TUMT) in benign prostatic hyperplasia: placebo versus TUMT. Urology 1994; 44: 58–63.
- de la Rosette JJMCH, Tubaro A, flöfner K, Carter S. Transurethral microwave thermotherapy: past, present and future. World J Urol 1994; 12: 352–6.
- d'Ancona FCH, Francisca EAE, Witjes WPJ, Welling L, Debruyne FMJ, de la Rosette JJMCH. High energy thermotherapy versus transurethral resection in the treatment of benign prostatic hyperplasia: results of a prospective randomized study with 1 year follow-up. J Urol 1997; 159: 120–5.
- Ahmed M, Bell T, Lawrence WT, Ward JP, Watson GM. Transurethral microwave thermotherapy (Prosta-tron version 2.5) compared with transurethral resection of the prostate for the treatment of benign prostatic hyperplasia: a randomized, controlled, parallel study. Br J Urol 1997; 79: 181–5.
- Stoner E. Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia. Urology 1994; 43: 284–94.
- Lepor H. Long-term efficacy and safety of terazosin in patients with benign prostatic hyperplasia. Urology 1995; 45: 406–15.